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R880very simple ancestor is a matter of
taste. Presumably there is an as-yet not
understood upper ‘‘speed limit’’ for
such rates, but Lee and colleagues [6]
point out that even the most elevated
rates recovered do not seem to go over
the limit for known rapid periods of
either morphological or molecular
evolution. As a result, one can indeed
have one’s evolutionary cake and eat
it — it is possible to squeeze the
radiation of the animals into a short
period of time just before and during
the Cambrian without having to invoke
any peculiar non-Darwinian
mechanisms to explain it.
Of course, this raises a further and
potentially even more interesting
question about how the elevated rates
of gene and morphological evolution
are related to each other. Lee et al. [6],
perhaps wisely, steer clear of
addressing this fraught issue directly,
and indeed previous attempts at
examining it have come to conflicting
conclusions [17,18]. However, themere
observation that both rates are
elevated is unlikely to be coincidental,
and suggests that, contrary to various
developmental scenarios where
large-scale morphological change in
the Cambrian explosion is driven by
a few changes in some key
developmental genes, theremust be an
ecological basis to it that would
naturally link the two rates. The
discovery that some molecular
evolutionary rates are elevated during a
particular interval of time will naturallyre-awaken some of the vexatious
issues around selection versus
neutrality in molecular evolution [19]. If
there is a true correlation between the
two rates, this could come about by a
variety of means [20], not all of which
involve direct causality. Exploring the
relationship between the two will in
future work surely add valued
ammunition to fire at the many
problems presented by early animal
evolution.References
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Substrates Hold Some of the AnswersThemechanismof action of themTOR inhibitor rapamycin is poorly understood
and why certain mTORC1 phosphorylation sites are rapamycin insensitive
remains elusive. Site-specific analysis of mTORC1 substrates now suggests
that the sequence composition of a phosphorylation site determines whether
it is sensitive to rapamycin and starvation.Sang-Oh Yoon1
and Philippe P. Roux2,3
Cells respond and actively adapt to a
variety of environmental and
intracellular stimuli, such as nutrients,
energy, oxygen and growth factors.
The mammalian target of rapamycin
complex 1 (mTORC1) integrates thesecues to regulate key anabolic and
catabolic processes, including protein,
lipid and nucleotide synthesis, as well
as autophagy [1,2]. Not surprisingly,
mTORC1 signaling is commonly
deregulated in human diseases,
including cancer and diabetes, making
mTOR an attractive therapeutic
target with numerous clinicalapplications. Extensive efforts to
develop improved analogs of the
mTOR inhibitor rapamycin — so-called
rapalogs — have resulted into two
types of FDA-approved molecules,
including temsirolimus (Torisel) and
everolimus (Afinitor). While these drugs
were found to be effective against
certain neoplasms, including advanced
kidney cancer and mantle cell
lymphoma, many types of cancer
respond poorly to rapalogs [3]. Given
the crucial role played by mTORC1 in
cell growth and proliferation, these
intriguing findings have fueled interest
in better understanding the elusive
mechanism of action of rapamycin.
Extensive studies have revealed that
mTORC1 phosphorylation substrates















































Figure 1. The quality of mTORC1 phosphorylation sites determines their sensitivity to rapamycin and to starvation from nutrients and growth
factors.
As reported in Kang et al. [6], mTORC1 phosphorylation sites that are poor in vitro substrates (e.g., S6K1 Thr389) tend to be more sensitive to
rapamycin treatment and to starvation from nutrients and growth factors. Conversely, phosphorylation sites that are good in vitro substrates of
mTORC1 (e.g., 4E-BP1 Thr37 and Thr46) appear insensitive to rapamycin treatment because the partial mTORC1 inhibition is not sufficient to
result in their complete dephosphorylation.
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R881treatment [4,5], suggesting that
they might be regulated by additional
factors (e.g., other kinases or
phosphatases) and/or that a
rapamycin-resistant form of mTORC1
may exist. This conundrum has been
partly solved by a recent study by Kang
et al. [6], which found that the inherent
capacity of a phosphorylation site to
serve as an mTORC1 substrate is a key
determinant of its sensitivity to
rapamycin (Figure 1). In other words,
the authors suggest that the
insensitivity of certain mTORC1
phosphorylation sites partly results
from the incomplete inhibition of
mTORC1 by rapamycin and the
persistence of phosphorylation, rather
than from the presence of a
rapamycin-insensitive form of
mTORC1. However, one possible
alternative explanation is that
rapamycin may be more potent at
inhibiting substrates that require the
FKBP12-rapamycin-binding (FRB)
domain for their recruitment to
mTORC1, as recently suggested by the
crystal structure of mTOR [7].
Before we explore these recent
findings in more detail, a little
background on mTORC1 substrates
and their differential regulation by
rapamycin is in order. mTORC1, which
is composed of mTOR, Raptor andmLST8, controls cell growth in part
through two downstream
substrates — the ribosomal S6 kinases
(S6Ks) and the eukaryotic translation
initiation factor 4E (eIF4E)-binding
proteins (4E-BPs) [8]. One of the S6K
isoforms, S6K1, plays important roles
in cell growth, proliferation and
differentiation by regulating different
aspects of translational control, cell
cycle progression and metabolism [9].
Therefore, aberrant activation of S6K1
is a key contributor to the progression
of tumors, diabetes and obesity [10],
and S6K1 inhibition increases lifespan
and reduces the incidence of
age-related pathologies [11]. The
4E-BPs appear to have the most
profound effect on protein synthesis
downstream of mTORC1, as they bind
to the cap-binding protein eIF4E and
thereby prevent cap-dependent
translation [8]. The phosphorylation of
the 4E-BPs by mTORC1 stimulates
their release from eIF4E, allowing
translation initiation to proceed. Similar
to the S6Ks, the 4E-BPs were shown to
play roles in neoplastic growth and
proliferation [12] andwere also found to
be critical regulators of lifespan and
aging [13]. Recent phosphoproteomics
studies have identified several putative
mTORC1 substrates, including growth
factor receptor-bound protein 10(Grb10), which functions as a negative
regulator of growth factor signaling
[14,15]. To this list of bona fide
mTORC1 substrates can be added
PRAS40 and ULK1, which were found
to regulate mTORC1 activity and
autophagy, respectively. There is little
doubt that many more mTORC1
substrates exist, including the
RNA-binding proteins LARP1 and
PATL1 [6,14,15], but the function and
regulation of these proteins remain to
be characterized.
While rapamycin has been an
indispensable tool for investigating the
role of mTORC1, its biological effect
varies widely between cell types. In
yeast, the effect of rapamycin is much
more pronounced than in mammals, as
it suppresses protein synthesis by
nearly 80% [5]. These differences
suggested at the time that mTORC1
activity may be less important in
mammalian cells; however, the
discovery of ATP-competitive mTOR
inhibitors and the finding that they
more significantly inhibit protein
synthesis inmammalian cells corrected
this view. Instead, it was thought that
mTORC2 or a rapamycin-insensitive
form of mTORC1 may explain the
reduced response to rapamycin. The
fact that ATP-competitive mTOR
inhibitors were found to have similar
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functional mTORC2 (i.e., cells deleted
for Sin1 or Rictor) gave support to the
latter possibility. At a molecular level,
S6K1 activity and its phosphorylation
at Thr389 is known to be sensitive to
rapamycin in most cell types [16].
However, the site-specific regulation of
4E-BP1 phosphorylation is much more
complex and appears to be
differentially regulated by rapamycin
treatment. While rapamycin treatment
leads to the rapid dephosphorylation of
Ser65 and Thr70 on 4E-BP1, Thr37 and
Thr46 were shown to be mostly
insensitive to rapamycin in many cell
types [4]. The finding that
ATP-competitive mTOR inhibitors and
Raptor depletion result in the complete
dephosphorylation of both S6K1 and
4E-BP1 led to the suggestion that
Thr37 and Thr46 may be regulated by
a rapamycin-insensitive form of
mTORC1, a view that has now been
re-evaluated in the recent study by
Kang et al. [6]. By introducing subtle
mutations into bona fide mTORC1
phosphorylation sites, the authors
were able to show that certain sites
considered to be rapamycin-sensitive,
such as Thr389 in S6K1, become more
resistant to rapamycin treatment.
Using mTORC1 in vitro kinase assays
and short synthetic peptides
encompassing single mTORC1
phosphorylation sites, the authors
were able to see a correlation between
better in vitro substrates of mTORC1
(i.e., substrates of high quality) and
their insensitivity to rapamycin. These
results suggest that the apparent
insensitivity of mTORC1
phosphorylation sites may be due to
the fact that stronger mTORC1
inhibition is required to observe their
dephosphorylation. These differences
are visible at the level of individual
sites and not full-length proteins
because substrates such as 4E-BP1
have both rapamycin-sensitive
and rapamycin-resistant sites.
Interestingly, the authors found that
rapamycin-insensitive sites were also
less sensitive to nutrient and growth
factor starvation, suggesting that
intrinsic differences between mTORC1
substrates, and more particularly
between their phosphorylation sites,
may help to coordinate the cellular
response to starvation.
These findings add to our
understanding of the multiple
mechanisms by which rapamycin
ineffectiveness or resistance mayoccur in many cancer types. While
these findings provide an explanation
as to why certain mTORC1 substrates
are differentially affected by rapamycin
treatment, some important questions
remain regarding why substrates such
as 4E-BP1 appear to be rapamycin
sensitive in some cell types but not in
others. Are there other factors involved
in substrate quality and/or rapamycin’s
inhibitory potency that are dependent
on the cellular context? Could FKBP12
protein levels be limiting in some cell
types but not in others? To overcome
weaker effects and incomplete
inhibition of mTORC1 by allosteric
inhibitors (e.g. rapamycin and
rapalogs), ATP-competitive mTOR
inhibitors that potently and
comprehensively block mTOR have
been developed [3]. Although these
inhibitors show a stronger effect than
rapamycin on tumor progression,
recent studies using a panel of over 600
cancer cell lines show that a large
portion of cell lines (40% in the case of
colorectal cancer) are resistant to these
inhibitors, and this resistance is
correlated with the inability of these
inhibitors to block 4E-BP1
phosphorylation [17,18]. As suggested
by Kang et al. [6], phosphorylation of
mTORC1 substrates is subject to
multiple regulatory mechanisms that
extend far beyond the simple sequence
motif of each phosphorylation site. In
the case of 4E-BP1, which is regarded
as a point of convergence of various
signaling pathways [19], it is possible
that there are other kinases
cooperating with mTORC1 to regulate
its phosphorylation. We have recently
shown that GSK3b phosphorylates
4E-BP1 at Thr37 and Thr46 and thereby
decreases its association with eIF4E
[20], suggesting that the regulation
of mTORC1 substrates may be
multifactorial and thus highly
dependent on the cellular context.
Indeed, it is plausible to assume that
cancer cells adapt by deregulating
additional kinases, such as GSK3b,
that substitute for mTORC1 in the
phosphorylation and inactivation of
some mTORC1 substrates, such as
4E-BP1.
Since its isolation in 1975,
rapamycin has been used for its
immunosuppressive and anti-cancer
properties. Rapamycin and the
rapalogs have also received recent
attention because of their potential in
the management of diabetes, lifespan
and neurological disorders [3]. Therecent report by Kang et al. [6] refines
our understanding of mTORC1 and its
substrates, and helps understand the
molecular mechanisms that underlie
rapamycin resistance. Considering
the biological and clinical significance
of rapamycin, these insights will likely
help in the design of more potent
therapeutic strategies for a number
of human diseases.References
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to Let GoTo ensure accurate chromosome segregation, cohesion between sister
chromatids must be released in a controlled manner during mitosis. A new
study reveals how distinct centromere populations of the cohesin protector
Sgo1 are regulated by microtubule attachments, cyclin-dependent kinases,
and the kinetochore kinase Bub1.Jonathan M.G. Higgins
Dividing cells must convey the correct
complement of chromosomes to their
offspring. Eukaryotes accomplish this
by maintaining cohesion between
replicated sister chromatids until
chromosomes are bi-oriented on the
mitotic spindle. Only once this has
been accomplished are the
attachments between chromatids
released, allowing them to be sorted
accurately to opposite poles of the
dividing cell. Clearly then, although
sister chromatids may be inseparable
at first, they must learn to let go when
the time comes. A report from Liu, Jia
and Yu in this issue of Current Biology
[1] provides new insight into this
process that may have broader
implications for our understanding of
inner centromere function.
Cohesion between sister chromatids
is maintained by cohesin complexes,
together with regulators such as
Sororin [2]. In vertebrate mitosis,
cohesin is removed from
chromosomes in two steps. In
prophase, a mechanism involving
phosphorylation of cohesin and Sororin
by mitotic kinases removes the bulk of
cohesin from chromosome arms
(Figure 1). Cohesin at centromeres,
however, is protected by Sgo1–PP2A
phosphatase complexes that
counteract phosphorylation of cohesinand Sororin [3–5]. To fully separate
chromatids at anaphase, the remaining
cohesin is cleaved by the protease
Separase [2]. This raises the question
of how cleavage of centromeric
cohesin is limited to anaphase. A
simple possibility is that Separase only
becomes active at anaphase, and that
Sgo1 does not protect cohesin from
cleavage in mitosis. However, it has
been reported that Sgo1, when
inappropriately maintained at inner
centromeres, prevents
Separase-mediated cohesin cleavage
[6]. Also, at least in budding yeast,
Sgo1–PP2A complexes may inhibit
Separase more directly [7]. Therefore,
it is important to understand how the
localization and activity of Sgo1 are
regulated.
During prophase in mammalian cells,
Sgo1 is found at inner centromeres
(defined here as the area between the
chromatin regions that contain
centromeric histone CENP-A; Figure 1).
As chromosomes become bi-oriented,
Sgo1 appears to move outwards,
relocating to two regions roughly
coinciding with CENP-A-containing
chromatin underlying kinetochores
[1,6,8]. This movement of Sgo1 away
from cohesin complexes located at
inner centromeres might render
cohesin susceptible to cleavage by
Separase, and would provide a way to
make removal of cohesin favorableonly when chromosomes are correctly
bi-oriented and microtubules exert
tension across sister kinetochores [6].
How this relocation of Sgo1 is
controlled, however, has been
unknown.
A number of ways to recruit Sgo1
to centromeres have been reported,
but the relative contributions of these
pathways are debated. It is widely
accepted that Sgo1 is brought to
centromeres when histone H2A is
phosphorylated at Thr-120
(H2AT120ph) by the kinetochore kinase
Bub1 [9,10], though the structural basis
for this recruitment is unknown. Sgo1
can also bind to the heterochromatin
protein HP1, which itself binds
chromatin by recognizing histone H3
trimethylated on Lys-9 (H3K9me3) [11].
Although most HP1 is removed from
chromosomes during mitosis, a
small population remains at inner
centromeres that could recruit Sgo1.
However, other studies have found that
key H3K9 methyltransferases are not
required for HP1 or Sgo1 localization in
mitosis [12,13], and that HP1 binds to
mitotic centromeres via the
chromosomal passenger complex
(CPC) in a manner that excludes HP1
binding to Sgo1 [14]. An alternative
potential contribution to inner
centromere Sgo1 localization is binding
to cohesin itself, an interaction that
depends on phosphorylation of Sgo1 at
Thr-346 by cyclin-dependent kinases
(Cdk) [5]. How do these proposed
mechanisms act together to control
Sgo1 function?
Although the dependency of Sgo1
localization on Bub1 activity is largely
unquestioned, the reason that
centromeric cohesion depends on
Bub1 is less clear [15,16]. Bub1 is a
mitotic checkpoint protein, and
lowering Bub1 levels might lead to
